1978 - MBBS (Hons) University of New South Wales Australia
1980 - FRACS Part I
1980 - VQE
1988 - FRACS (Urology) Part II
Professor Stricker, AO, is a urologist and the Director of the St Vincent’s Prostate Cancer Centre and Chairman of the Department of Urology at St Vincent’s Private Hospital and Clinic. He is one of the leading experts in the treatment of prostate cancer in Australasia. In 2006 he commenced the first robotic program in NSW at St Vincent’s Hospital and has since performed over 2,000 robotic prostate cancer cases. He continues to perform open surgery and has currently performed in excess of 4,500 open radical prostatectomies.
Professor Stricker has extensive experience in performing low-dose rate and high dose-rate brachytherapy, designing and managing structured active surveillance programs, and has been one of the Australian pioneers in the introduction of focal therapy using irreversible electroporation to treat prostate cancer.
Professor Stricker’s area of research focuses on the quality of life in patients following treatment, perfecting surgical techniques, the introduction of less invasive surgical techniques, utilising medical imagining for the detection and evaluation of prostate cancer and tailoring therapy for all patients with prostate cancer. He has authored over 160 peer reviewed publications, has collaborative research ties within Australia and Overseas and has been involved with numerous successful grant funding applications.
Conjoint Associate Professor, Department of Surgery, University of New South Wales Australia
Clinical Associate Professor, Sydney Medical School, University of Sydney
Clinical Professor, School of Health Sciences, University of Tasmania
Conjoint Professor, School of Medicine, University of Western Sydney
2010 - 2014 - NHMRC Enabling Grant (ID No. 614296). "Australian Prostate Cancer Collaboration (APCC) Bio-Resource”. Clements J, Sutherland RL, Tilley W, Risbridger G, Marshall V, Roder D, Stahl J, Gardiner F, Nicol D, Frydenberg M, Pedersen J, Stricker P. $2,000,000.00
2010 – 2015 – Cancer Institute NSW Program Grant for Excellence in Translational Research. Personalised medicine for cancer: molecular biomarkers in clinical decision making for breast, prostate and pancreatic cancer. CIs: Horvath LG, Kench J, Boyer M, Millar E, O’Toole S, Beith J, Grimison P. AI: Stricker P. $3,750,000.00
2012 – 2013 - St Vincent’s Clinic Foundation “K & A Collins” Grant. MRI Study. Stricker P. $50,000.00
2013 – 2017 - Federal Government Grant – “The Chronic Disease Prevention and Service Improvement”. Australian Prostate Cancer Research Centre NSW. Mattick J, Spigelman A, Stricker P, Hayes V, Horvath L. $5,500,000.00
2016 – 2017 - NHMRC Project Grant – “Epigenetic Changes in the Prostate Cancer Environment”. Clark S, Horvath L, Kench J, Stricker P et al. $848,954.00
2016 – 2017 - Paul Ramsay Foundation – “Magnifi Trial”. Van Leeuwen P and Stricker P. $759,000.00
2016 – 2017 - Paul Ramsay Foundation – “LuPSMA Trial”. Emmett L and Stricker P. $400,000.00
2017 – 2018 - The John and Denise Cobcroft Cancer Research Grant/St Vincent’s Clinic Grant- “DETECT trial: Radioguided surgery with technetium99m-labelled PSMA to aid intra-operative lymph node metastases detection for patients undergoing robot-assisted radical prostatectomy and extended-pelvic lymph node dissection for prostate cancer”. Stricker P and Co-investigators. $30,000.00
2017 – 2018 - Commonwealth Department of Health: Cancer Control – Australian Prostate Cancer Research Centres. Stricker P, Hayes V, Horvath L, Clarke S, Kench J, Joshua A, Rashiah K, Nguyen Q. $1,500,000.00
2019 - Commonwealth Department of Health: Australian Prostate Cancer Research Centre. Stricker P, Hayes V, Horvath L, Clarke S, Joshua A, Emmet L - $437,000.00
2019 – 2020 - St. Vincent’s Clinic Foundation Grant. PRIMARY Trial – Can combined multiparametric MRI and PSMA PET imaging replace prostate biopsy in the primary diagnosis of prostate cancer? Emmett L and Stricker P. $40,000.00
2019 – 2020 - St Vincent’s Curran Foundation Grant. PRIMARY Trial – A prospective evaluation of prostate-specific membrane antigen positron emission tomography (PSMA PET) to reduce unnecessary prostate biopsies in men at risk of prostate cancer.
Emmett L and Stricker P. $100,000.00
2019 – 2021 - The Sydney Partnership for Health, Education, Research & Enterprise (SPHERE) – Additional diagnostic value of PSMA to mpMRI in the diagnostic setting: Ability to reduce unnecessary prostate biopsies in men being investigated for prostate cancer. PRIMARY Trial. Emmet L and Stricker P. $150,000.00